MedImmune's ex-CEO, David Mott, is starting a new career as a venture capitalist. He's been named a general partner at New Enterprise Associates, a busy investor in the biotech field. Mott says he will focus on biotechnology and specialty pharma.
Mott left MedImmune last July, a year after it was bought out by AstraZeneca for $15.6 billion. And the acquisition didn't leave Mott hurting for money. He got $133.5 million in stock option payouts and $12.2 million in other money.
"His broad sector expertise and strong ties within the biopharma community add substantial depth to NEA's healthcare practice," Peter J. Barris, a managing general partner, said in a statement.
- see NEA's release
- read the story from the Washington Post